PLX
- Protalix BioTherapeutics, Inc.
()
Overview
Company Summary
Protalix BioTherapeutics, Inc. (PLX) is a biopharmaceutical company that is primarily engaged in the development and commercialization of innovative recombinant therapeutic proteins.
The company specializes in using its proprietary ProCellEx� protein expression system to produce complex therapeutic proteins in plant cell cultures. This unique and advanced technology allows Protalix to manufacture large quantities of high-quality proteins that are used in the development of potential drug candidates.
Protalix's main focus is on developing recombinant proteins for the treatment of various rare and severe genetic diseases. The company's flagship product, Elelyso (taliglucerase alfa), is an enzyme replacement therapy used for the treatment of Gaucher disease, a rare genetic disorder.
Protalix is also actively involved in the development of other promising therapies. In collaboration with Chiesi Farmaceutici SpA, the company is working on PRX-102, an investigational recombinant protein indicated for the treatment of Fabry disease, another rare genetic condition. Additionally, Protalix is exploring potential treatments for Cystic Fibrosis, and has other preclinical programs, including potential therapies for immune disorders and certain types of cancers.
The company's commitment to innovation extends beyond its product portfolio. Protalix's ProCellEx technology also offers the potential to produce vaccines, antibodies, and other therapeutic proteins, providing a platform for future growth and partnerships in the pharmaceutical industry.
Overall, Protalix BioTherapeutics focuses on developing and commercializing advanced therapies for rare diseases, using its proprietary ProCellEx protein expression system, and continually exploring new avenues for therapeutic proteins to improve patients' lives.